Evidence map›Paper›PMID 40393442›Full record

ArticleThe American journal of tropical medicine and hygiene2025

Transmission Dynamics of Mpox in Peru During the 2022 Outbreak.

M Gabriela Soto-Cabezas, Adrián Vásquez-Mejía, Martha Calderón, Mary Reyes-Vega, Yrene I Blancas-Blas, Anderson N Soriano-Moreno, María A Vargas, Kely R Meza, Jorge R Uchuya, Diego Castro-Garro and 3 more

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

M Gabriela Soto-CabezasCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Adrián Vásquez-MejíaCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Martha CalderónCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Mary Reyes-VegaCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Yrene I Blancas-BlasCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Anderson N Soriano-MorenoCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
María A VargasCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Kely R MezaCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Jorge R UchuyaCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Diego Castro-GarroCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Sergio Luque-MamaniCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Oswaldo G E Espinoza-HurtadoCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.
Cesar V MunaycoCentro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In July 2022, mpox was declared an international public health emergency because of a surge in cases across Europe and America. This study assessed transmission dynamics and factors associated with hospitalization during the 2022 mpox outbreak in Peru. We performed a cross-sectional study using the Surveillance System of the National Center of Epidemiology, Prevention, and Disease Control (CDC-Peru) data. We estimated the basic reproduction number (R0), effective reproduction number (Rt), and the duration of the outbreak phases. We conducted mathematical modeling of the outbreak and estimated the serial interval. Additionally, we used Poisson regression with robust variance to identify hospitalization factors, using prevalence ratio. Between July and December 2022, 3,677 confirmed cases (96.3% male, mean age 32.6 years) were reported to the CDC-Peru. Of these, 75.0% were men who have sex with men (MSM), 55.6% had HIV infection, and 5.2% were hospitalized. The R0 was 2.37, with an exponential growth phase lasting 7 weeks, and Rt dropped to non-epidemic levels after 14 weeks. The incubation period and recovery period were estimated to be 6 days and 22 days, respectively. The serial interval was 9.3 days. HIV infection increased hospitalization risk. The 2022 mpox outbreak in Peru was characterized by primarily affecting a young MSM population, with a significant proportion being people living with HIV. Hospitalization was associated with HIV coinfection. This outbreak showed exponential growth during the first 7 weeks, followed by a marked deceleration of transmission.

Indexed as

Disease OutbreaksMpox, MonkeypoxAdolescentAdultBasic Reproduction NumberCross-Sectional StudiesFemaleHIV InfectionsHomosexuality, MaleHospitalizationHumansMaleMiddle AgedPeruYoung Adult

Identifiers

PMID40393442
PMCPMC12360102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.